Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 3/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14166087 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL4522895 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL18047346 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL10705966 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL3213711 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14166088 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2983518 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1543565 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1543564 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28410100 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-109715609-B | Cyclohexylbenzamide compounds | 伊莱利利公司 | 2023-01-10 | — | — | CN | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070197605-A1 | ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-7091221-B2 | Partial ester of cellulose with nitrogenous carboxylic acid and process for producing the same | AJINOMOTO CO., INC. (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| US-20030027733-A1 | Partial ester of cellulose with nitrogenous carboxylic acid and process for producing the same | AJINOMOTO CO., INC. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-1270598-A1 | PARTIAL ESTER OF CELLULOSE WITH NITROGENOUS CARBOXYLIC ACID AND PROCESS FOR PRODUCING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0081838-B1 | CYCLOHEXYL AND PHENYL SUBSTITUTED ENKEPHALINS | G.D. Searle & Co. (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4407746-A | Cyclohexyl and phenyl substituted enkephalins | G. D. SEARLE & CO. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0081838-A1 | Cyclohexyl and phenyl substituted enkephalins | G.D. Searle & Co. (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197605-A1 | ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, GPR119 | CHRNB4 3596/4885CHRNA3 2008/4885CHRNA7 1739/4885 |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | CHRNB4 1040/4885CHRNA3 398/4885CHRNA7 693/4885 |
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CHRNB4 4434/4885CHRNA3 3977/4885CHRNA7 3732/4885 |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | CHRNB4 4452/4885CHRNA3 4512/4885CHRNA7 4643/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | CHRNB4 1040/4885CHRNA3 398/4885CHRNA7 693/4885 |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | CHRNB4 1040/4885CHRNA3 398/4885CHRNA7 693/4885 |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | EP300, CREBBP, BRD3 | CHRNB4 1040/4885CHRNA3 398/4885CHRNA7 693/4885 |
| US-20030027733-A1 | Partial ester of cellulose with nitrogenous carboxylic acid and process for producing the same | NRDC, FASN, Q6ZSR9 | CHRNB4 1586/4885CHRNA3 2184/4885CHRNA7 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.